Brokerages predict that Karyopharm Therapeutics Inc. (NASDAQ:KPTI) will post ($0.64) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Karyopharm Therapeutics’ earnings. The lowest EPS estimate is ($0.69) and the highest is ($0.60). Karyopharm Therapeutics posted earnings of ($0.84) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 23.8%. The company is scheduled to issue its next quarterly earnings report on Thursday, August 3rd.

According to Zacks, analysts expect that Karyopharm Therapeutics will report full-year earnings of ($2.63) per share for the current fiscal year, with EPS estimates ranging from ($2.81) to ($2.47). For the next fiscal year, analysts forecast that the company will post earnings of ($2.61) per share, with EPS estimates ranging from ($2.90) to ($2.36). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Karyopharm Therapeutics.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by $0.04. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.02 million. Karyopharm Therapeutics had a negative net margin of 50,646.40% and a negative return on equity of 72.41%. During the same period in the previous year, the company earned ($0.75) earnings per share.

A number of research firms have recently weighed in on KPTI. Zacks Investment Research downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Saturday, June 24th. Jefferies Group LLC restated a “buy” rating and issued a $16.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, July 14th. Robert W. Baird restated an “outperform” rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a research note on Tuesday, July 4th. Finally, ValuEngine downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 25th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Karyopharm Therapeutics currently has an average rating of “Buy” and an average target price of $14.46.

Large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. acquired a new stake in Karyopharm Therapeutics during the fourth quarter valued at approximately $343,000. State Street Corp increased its stake in Karyopharm Therapeutics by 6.6% in the fourth quarter. State Street Corp now owns 406,103 shares of the company’s stock valued at $3,820,000 after buying an additional 25,015 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Karyopharm Therapeutics by 347.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 261,055 shares of the company’s stock valued at $2,454,000 after buying an additional 202,714 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its stake in Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock valued at $206,000 after buying an additional 2,460 shares in the last quarter. Finally, Teachers Advisors LLC increased its stake in Karyopharm Therapeutics by 15.0% in the fourth quarter. Teachers Advisors LLC now owns 41,436 shares of the company’s stock valued at $389,000 after buying an additional 5,419 shares in the last quarter. Institutional investors and hedge funds own 57.01% of the company’s stock.

Shares of Karyopharm Therapeutics (KPTI) traded down 0.54% during trading on Wednesday, hitting $9.14. 55,904 shares of the stock traded hands. Karyopharm Therapeutics has a 1-year low of $6.27 and a 1-year high of $14.63. The stock’s market cap is $430.66 million. The stock has a 50 day moving average price of $9.33 and a 200-day moving average price of $10.19.

TRADEMARK VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/07/26/karyopharm-therapeutics-inc-nasdaqkpti-expected-to-post-earnings-of-0-64-per-share.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.